Hypokalemia

Hypokalemia — a serum potassium below 3.5 mEq/L — is one of the most common electrolyte abnormalities in clinical practice. Like hyperkalemia, it kills through cardiac arrhythmia: flattened T waves, prominent U waves, ST depression, and — in severe cases — ventricular tachycardia, torsades de pointes, and ventricular fibrillation.

The serum potassium is a poor reflection of total body potassium. Approximately 98% of total body potassium is intracellular. A serum potassium of 3.0 mEq/L may represent a total body deficit of 200–400 mEq. A serum potassium of 2.5 mEq/L may represent a deficit of 400–600 mEq or more. This means that repletion requires more potassium than the serum level alone suggests — and that the serum level can normalize before total body stores are replenished.

The clinical significance of hypokalemia depends on the absolute level, the rate of fall, the underlying cardiac substrate, and concurrent electrolyte abnormalities. Patients with heart disease, those on digoxin, and those with concurrent hypomagnesemia are at highest risk for arrhythmia at any given potassium level.

Hypokalemia results from three mechanisms: transcellular shift (potassium moves into cells without a change in total body potassium), increased renal losses, and increased GI losses.

Transcellular shift is caused by alkalosis (for every 0.1-unit rise in pH, potassium falls by approximately 0.3–0.5 mEq/L), insulin (drives potassium into cells via Na-K-ATPase), beta-2 adrenergic stimulation (endogenous catecholamines in stress, or exogenous albuterol), and hypokalemic periodic paralysis. Shift-related hypokalemia does not reflect true potassium depletion — treating the underlying cause reverses it.

Increased renal losses are the most common cause of true potassium depletion. Diuretics — both thiazide and loop — are the most common culprit in outpatients. Primary and secondary hyperaldosteronism (including Cushing syndrome and exogenous corticosteroids) cause renal potassium wasting through aldosterone-mediated collecting duct secretion. Renal tubular acidosis (particularly type 1 and type 2) causes potassium wasting. Hypomagnesemia causes renal potassium wasting that is refractory to potassium repletion alone.

Increased GI losses from vomiting, nasogastric suction, and diarrhea cause hypokalemia through different mechanisms. Vomiting and NG suction cause metabolic alkalosis, which drives renal potassium wasting — the direct potassium loss in gastric fluid is actually small. Diarrhea causes direct potassium loss in stool, often with metabolic acidosis.

When the cause of hypokalemia is not clinically obvious, urine potassium studies help distinguish renal from extrarenal losses. A spot urine potassium-to-creatinine ratio above 13 mEq/g (or a urine potassium above 20 mEq/L in a random specimen) suggests inappropriate renal potassium wasting — the kidney is losing potassium when it should be conserving it. A low urine potassium suggests extrarenal losses (GI) or transcellular shift.

The transtubular potassium gradient (TTKG) is an older calculation that attempts to estimate collecting duct potassium secretion, but it has significant limitations and is less commonly used in current practice.

Concurrent acid-base status helps narrow the differential. Hypokalemia with metabolic alkalosis suggests vomiting, NG suction, diuretics, or hyperaldosteronism. Hypokalemia with metabolic acidosis suggests diarrhea, renal tubular acidosis, or diabetic ketoacidosis (where total body potassium is depleted despite a potentially normal or high serum potassium at presentation due to acidosis-driven shift).

The goal of treatment is to restore total body potassium stores, prevent arrhythmia, and address the underlying cause. Repletion alone without addressing the cause leads to recurrence.

Oral potassium chloride is the preferred route for mild to moderate hypokalemia (potassium 3.0–3.5 mEq/L) in hemodynamically stable patients without active arrhythmia. It is safer, more physiologic, and avoids the risks of IV administration. Typical doses are 40–80 mEq orally in divided doses. Potassium chloride is preferred over potassium bicarbonate or citrate in most settings because chloride depletion often coexists with hypokalemia (particularly in diuretic-induced or vomiting-related cases).

IV potassium is reserved for severe hypokalemia (potassium below 2.5–3.0 mEq/L), inability to take oral medications, active cardiac arrhythmia, or symptomatic hypokalemia. IV potassium must be given slowly — no more than 10–20 mEq/hour through a peripheral line to avoid phlebitis and cardiac toxicity. Rates above 20 mEq/hour require central access and continuous cardiac monitoring.

Check and correct magnesium before or concurrently with potassium repletion. Hypomagnesemia causes renal potassium wasting through impaired Na-K-ATPase function. Potassium repletion will be ineffective and short-lived if magnesium is not corrected. This is one of the most commonly missed steps in hypokalemia management.

EKG changes in hypokalemia include flattened or inverted T waves, prominent U waves (a positive deflection after the T wave, best seen in V2–V3), ST depression, and prolonged QU interval. These changes are neither sensitive nor specific — a normal EKG does not exclude clinically significant hypokalemia, and EKG changes do not reliably predict arrhythmia risk.

Patients with severe hypokalemia (below 2.5 mEq/L), EKG changes, active cardiac disease, or those on digoxin require continuous cardiac monitoring during repletion. Digoxin toxicity is potentiated by hypokalemia — digoxin competes with potassium for the Na-K-ATPase pump, and low potassium increases digoxin binding and toxicity.

Recheck potassium 2–4 hours after IV repletion and 4–6 hours after oral repletion to assess response. Repeat repletion as needed. In patients with ongoing losses (active diuresis, ongoing diarrhea), repletion must be ongoing rather than a single correction.